| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/BMC.3968 |
| P698 | PubMed publication ID | 28266722 |
| P50 | author | Margarete Silva Gracia | Q89425800 |
| P2093 | author name string | Ekkehard Haen | |
| Sandra Unholzer | |||
| Alexandra Köppl | |||
| P2860 | cites work | Alteration of propranolol pharmacokinetics and pharmacodynamics by quinidine in man | Q28328927 |
| Olanzapine. Pharmacokinetic and pharmacodynamic profile. | Q33747095 | ||
| The effects of beta-adrenoceptor antagonists and levomepromazine on the metabolic ratio of debrisoquine | Q34357697 | ||
| Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics | Q34563883 | ||
| Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients | Q35711359 | ||
| The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension | Q36025103 | ||
| Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. | Q37378059 | ||
| Melperone but not bisoprolol or metoprolol is a clinically relevant inhibitor of CYP2D6: evidence from a therapeutic drug monitoring survey | Q40976937 | ||
| Variable contribution of CYP2D6 to the N-dealkylation of S-(-)-propranolol by human liver microsomes | Q41943419 | ||
| Perpetrators of pharmacokinetic drug-drug interactions arising from altered cytochrome P450 activity: a criteria-based assessment. | Q42146760 | ||
| Inhibition of antipyrine metabolism by beta-adrenoceptor antagonists | Q42285279 | ||
| A pharmacokinetic and pharmacodynamic interaction study between nebivolol and the H2-receptor antagonists cimetidine and ranitidine | Q42625060 | ||
| Differential effect of continuous administration of beta-adrenoceptor antagonists on antipyrine and phenytoin clearance. | Q43222657 | ||
| Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach | Q43817449 | ||
| Propranolol-induced lipid changes and their prognostic significance after a myocardial infarction: the Beta-Blocker Heart Attack Trial experience | Q44188790 | ||
| Serum glucose and lipid changes during the course of clozapine treatment: the effect of concurrent beta-adrenergic antagonist treatment | Q44202996 | ||
| Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine | Q44364145 | ||
| Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study | Q47238068 | ||
| Beta-blockers and weight change in patients with chronic heart failure | Q47323620 | ||
| A clinical study of the association of antipsychotics with hyperlipidemia. | Q51906128 | ||
| Validation of bioanalytical chromatographic methods. | Q52241061 | ||
| Metabolic effects of pindolol and propranolol in a double-blind cross-over study in hypertensive patients | Q54265585 | ||
| Pharmacokinetics and Metabolism of Bisoprolol Enantiomers in Humans | Q56620130 | ||
| Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugs | Q56657883 | ||
| Timolol Metabolism in Human Liver Microsomes Is Mediated Principally by CYP2D6 | Q58734950 | ||
| P433 | issue | 10 | |
| P577 | publication date | 2017-04-03 | |
| P1433 | published in | Biomedical Chromatography | Q4915104 |
| P1476 | title | Development and validation of an HPLC-UV method for the simultaneous determination of the antipsychotics clozapine, olanzapine and quetiapine, several beta-blockers and their metabolites | |
| P478 | volume | 31 |
Search more.